Author: Medical Editor Jason
Advantages and recent developments of treating bone marrow fibrosis in the United States
Leading hospitals and experts in the U.S. for treating bone marrow fibrosis
Asian Myelofibrosis Patients Remote Video Consultation with American Experts
Medebound HEALTH: Connecting You with the World's Top Medical Resources
What is Myelofibrosis? How high is the incidence rate?
Myelofibrosis (Primary Myelofibrosis, PMF) is a type of chronic myeloproliferative neoplasm, which is a kind of myeloproliferative neoplasm (MPN). It is caused by the abnormal proliferation of fibrous tissue in the bone marrow, leading to impaired normal hematopoietic function, thuscausing symptoms such as anemia, splenomegaly, and bone pain. There are approximately0.5-1.5 new cases per 100,000 people worldwide each year, mostly seen in people over50 years old.
How is Myelofibrosis Treated?
The main treatments for myelofibrosis include:
Medication Treatment: JAK inhibitors (such as ruxolitinib) are the main targeted treatment drugs, which can improve symptoms and splenomegaly.
Supportive Treatment: Such as erythropoietin to improve anemia, low-dose aspirin to prevent thrombosis.
Stem Cell Transplant: For young or high-risk patients, allogeneic hematopoietic stem cell transplantation is the only potentially curative method.
Can bone marrow fibrosis be cured?
Currently, bone marrow fibrosis is still an incurable disease, but early diagnosis and standardized treatment can significantly improve quality of life and extend survival time.Stem cell transplantation is a means for a few patients to achieve long-term remission or even cure.
Advantages and Latest Developments of Treating Bone Marrow Fibrosis in the USA
The USA is at the forefront of research and treatment for bone marrow fibrosis, boasting advanced medical technologies and extensive clinical experience. The following are the main advantages and latest developments in treating bone marrow fibrosis in the USA:
Advanced Targeted Drugs: The United States has pioneered the development and approval of several JAK inhibitors for the treatment of myelofibrosis, including Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib. These drugs can effectively relieve symptoms, reduce spleen size, and improve patients' quality of life.
Innovative Combination Therapies: Recent studies show that combining JAK inhibitors with novel drugs can enhance treatment efficacy. For example, Pelabresib (BET inhibitor) and Navitoclax (BCL-2 inhibitor);Ruxolitinib combined with Abemaciclib for myelofibrosis. Clinical trials of new drugs show promising prospects.
Individualized Treatment Plan: Top US medical institutions develop precise individualized treatment plans based on the patient's genetic test results, enhancing theeffectiveness and safety of the treatment.
Abundant Clinical Trial Opportunities: The US has numerous clinical trial projects, giving patients the opportunity to participate in the research of the latest therapies and access cutting-edge treatments. On ClinicalTrials.gov, the latest clinical studies about Myelofibrosis include various targeted and combination therapies, such as new drug research on JAK inhibitors, BCL-2 inhibitors, and BET inhibitors. In recent years, several renowned US medical institutions (such asMemorial Sloan Kettering Cancer Center, MD Anderson Cancer Center) have actively participated in relevant clinical trials. These studies aim to improve symptoms, prolong survival, and enhance quality of life. For more details, please see:ClinicalTrials.gov - Myelofibrosis
Advanced Stem Cell Transplantation Technology: For suitable patients, the Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) in the USA is mature and has a high success rate. It is currently the only potential cure for myelofibrosis.
Leading Hospitals and Specialists in the U.S. for Treating Myelofibrosis
Memorial Sloan Kettering Cancer Center (MSKCC)
Expert:Michael J. Mauro, MD
Specializes in: chronic myeloid leukemia, myelofibrosis, polycythemia vera, thrombocythemia, and other myeloproliferative disorders.
Dana-Farber Cancer Institute
Expert: Daniel J. DeAngelo, MD, PhD
Specializes in: Head of the Adult Leukemia Program, focusing on the diagnosis and treatment of acute and chronic leukemia, and myeloproliferative disorders.
Cost of Treating Myelofibrosis in the United States
The cost of treating myelofibrosis in the United States varies depending on the individual treatment plan. Here is the approximate cost range:
Teleconsultation Fees: Approximately$3,000-7,000.
Targeted Drug Therapy: Like the JAK inhibitor Ruxolitinib, the annual cost is approximately$60,000-120,000.
Stem Cell Transplant: Total cost for allogeneic hematopoietic stem cell transplantation is approximately$200,000-400,000.
Pain Points for International Patients with Myelofibrosis
1. Limited Treatment Options and Lack of Access to New Drugs and Clinical Trials
Lack of New Targeted Drugs: For example, JAK inhibitors (Ruxolitinib, Fedratinib) are not approved or unavailable in some countries, preventing patients from receiving cutting-edge treatment.
Restricted Access to Clinical Trials: Clinical research on new drugs (e.g., Pelabresib, Navitoclax) is mostly concentrated in the U.S. and Europe, making it difficult for patients to participate in new drug experiments or receive experimental therapies.
2. Diagnosis and Treatment Lack Precision and Personalization
Insufficient Genetic Testing and Molecular Diagnosis: Lack of comprehensive testing for gene mutations such as JAK2, CALR, MPL leads to a treatment plan that cannot be precisely tailored.
Standardized Treatment, Lack of Personalized Plans: Treatment plans in some areas are rather uniform and unable to be individually tailored to the patient's specific situation.
3. Scarcity of Stem Cell Transplant Resources
Difficulty in Matching: Limited bone marrow registry resources make it difficult to find donors for allogeneic hematopoietic stem cell transplants, delaying treatment opportunities.
Incomplete Transplant Technology and Subsequent Management: There is a relative lack of medical resources and experience in pre-transplant evaluations, transplant procedures, and postoperative care.
4. Shortage of Medical Resources and Experts
Lack of Authority Experts in Hematologic Oncology: Patients find it difficult to access top international hematology experts for professional treatment guidance.
Insufficient Specialized Medical Facilities: There is a lack of comprehensive treatment centers specifically for myelofibrosis.
5. Patient Education and Information Asymmetry
Insufficient Understanding of the Disease: Many patients have limited knowledge about the course of myelofibrosis, treatment methods, and may miss the best treatment timing.
Difficulty in Accessing Cutting-edge International Information: Hard to keep up with the latest global treatment progress, drug information, and clinical trial dynamics.
6. Insufficient Follow-up and Long-term Management
Inadequate Long-term Monitoring System: Lack of systematic management in post-treatment assessment, medication adjustment, and relapse warning.
Insufficient Cross-regional Medical Collaboration: Difficult to achieve joint consultation with domestic and international experts and dynamically adjust treatment plans.
So, is there a way to help patients reduce their burden?
Yes, indeed there is.
Case of Asian Myelofibrosis Patient with Remote Video Consultation with American Experts
Mr. Lu (alias),58 years old, was previously diagnosed with primary thrombocythemia (JAK2V617f positive), and recently presented with splenomegaly. A bone marrow biopsy indicated a tendency towards myelofibrosis. After consulting renowned doctors locally, the patient also sought expertise in Japan, but received inconsistent treatment plans. Therefore, Mr. Lu turned to American healthcare to find an authoritative doctor in the field of his illness to provide final guidance on his treatment plan and clarify the next steps in his treatment.
Under the recommendation of friends nearby, Mr. Lu's family found MEDEBOUND HEALTH, relying on 9 years of experience in overseas medical services, connected Mr. Lu to a hematology authority at Memorial Sloan Kettering Cancer Center, Dr. Michael J. Mauro, and arranged a 50-minute video consultation.
Remote Consultation Process: During the 50-minute video consultation, the MSKCC hematology expert clearly stated that the current treatment plan by Japanese experts has not been approved or marketed in the United States and is not a conventional treatment plan.
New Treatment Plan: The standard and best treatment is to initiate JAK inhibitor treatment alone, and two suitable medications for the patient were recommended, choosing one to use. Additionally, for the diagnosis of JAK2 mutation-positive primary thrombocythemia, it is advised to continue or start taking low-dose aspirin. Furthermore, supplementing with erythropoietin can be considered.
Monitoring Indicators Recommendations: Continuous spleen imaging, repeated molecular studies (gene testing), repeated BMBX assessments
Possible Future Combined Therapies: Promising combinations include Pelabresib (investigative BET inhibitor) from MANIFEST-2 Phase 3 study
Additionally, the professor mentioned recommendations for several clinical studies at the Memorial Sloan Kettering Cancer Center: including combination or monotherapy with the following drugs:PIM kinase inhibitor (TP3654), CDK4/6 inhibitors, Selinexor (XPO1 inhibitor), DISC0974 (hepcidin regulator)
Consultation Results: After the consultation, Mr. Lu's family acknowledged the expert's professional advice, clarified the direction for subsequent treatment, alleviated anxiety, and are full of confidence in future treatment.
Consultation Follow-Up
Consultation follow-up: Since July, Mr. Lu started JAK inhibitor treatment as recommended by Dr. Mauro. Currently,the condition is stable,spleen enlargement has eased and anemia symptoms have significantly improved. The patient undergoes regular spleen imaging checks and blood monitoring, with good therapeutic results. MEDEBOUND HEALTHcontinues to monitor the patient's recovery progress and help them access more treatment information.
Patient Testimonials
With the help ofMEDEBOUND HEALTH, I was able to directly communicate with top U.S. experts and identify the most suitable treatment plan for me. Now, my condition is stable, and I am full of confidence for the future. I am very thankful forMEDEBOUND HEALTH team's professionalism and patient support!
Medebound HEALTH How can we help you
1. Initial Consultation: Contact us to discuss your needs. Our care team will clearly explain all treatment options, helping you understand each choice without causing confusion or pressure.
2. Talk to the Doctor: We will arrange a remote video call with top experts from prestigious hospitals in the USA. No need to worry about language barriers, as we will provide professional translation services to ensure clear and comfortable communication about your condition and recovery expectations.
3. Create Your Treatment Plan: After talking to the doctor, we will assist you in creating a treatment plan. We will clearly explain which treatments may be beneficial, how long they will take, the costs involved, and the outcomes you can expect.
4.Travel Assistance: If you need to travel to the U.S. for treatment, we will simplify the whole process. We will handle visa applications, book flights, find comfortable accommodations near the hospital, arrange pickup services, and make all travel arrangements for your family.
5.Arrival at the Hospital: Once you arrive at the U.S. hospital, our team will be with you all the time. We will assist you in communicating with doctors, explaining treatment plans, supporting your family, and applying for the maximum discounts from the hospital through our many years of cooperation with U.S. hospitals. These discounts can sometimes reach 15%-50%, which may be much higher than the discounts a patient could secure individually.
6.Post-Treatment Support: Even after you return home, our care does not stop. We will assist with rehabilitation exercises, monitor your recovery progress, arrange communication with doctors if necessary, and support your recovery journey until you achieve your goals and fully recover.
Medebound HEALTH: Connecting You to the World's Top Medical Resources
If you or your family are seeking treatment for complex diseases from the world's top experts, Medebound HEALTH is your best choice. Through our partnerships with leading medical institutions in the US, whether it is remote video consultations or treatment in the US, we provide full support throughout the process.
Contact Us：
Website: https://www.medeboundhealth.com/
Toll-Free US Number: +19173101780
Or you can fill out the form below👇Our friendly team will quickly connect you with the right expert!
Your health deserves the best.Medebound HEALTH helps you easily achieve a top-notch medical journey!
Comentários